Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with significant unmet medical needs.</li><li>The company recently announced positive proof-of-concept data regarding the development of a novel artificial thymus organoid that restored immune function in a severe combined immunodeficiency (SCID) mouse model.</li><li>We continue to anticipate that a Phase 1/2 clinical trial of CYWC628, the company's lead asset targeting diabetic foot ulcers, will be completed in Australia in 2025.</li></ul>

FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with significant unmet medical needs.The company recently announced positive proof-of-concept data regarding the development of a novel artificial thymus organoid that restored immune function in a severe combined immunodeficiency (SCID) mouse model.We continue to anticipate that a Phase 1/2 clinical trial of CYWC628, the company's lead asset targeting diabetic foot ulcers, will be completed in Australia in 2025.

FBLG: Proof-of-Concept Data for Artificial Thymus Technology 

<ul>
<li>We are initiating coverage of FibroBiologics, Inc. (FBLG) with an $11.00 valuation.</li>
<li>FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with significant unmet medical needs.</li>
<li>We anticipate that a Phase 1/2 clinical trial of CYWC628, the company's lead asset targeting diabetic foot ulcers, will be completed in Australia in 2025.</li>
</ul>


We are initiating coverage of FibroBiologics, Inc. (FBLG) with an $11.00 valuation.
FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with significant unmet medical needs.
We anticipate that a Phase 1/2 clinical trial of CYWC628, the company's lead asset targeting diabetic foot ulcers, will be completed in Australia in 2025.


United States

FibroBiologics, Inc. operates as an early stage, cell therapy company. The Company develops food and drug administration trials related to fibroblast treatments for degenerative disc disease, multiple sclerosis, cancer, wound healing, and other diseases. FibroBiologics serves clients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

FibroBiologics (FBLG US)

FBLG: Proof-of-Concept Data for Artificial Thymus Technology

FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with...

Zacks Small Cap Research

FibroBiologics, Inc. - June 24, 2024

FibroBiologics is a cell therapy company focused on the development of fibroblast-based therapies for the treatment of chronic diseases with...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)